Insider trade

CEO exercised or converted 7,490 CYTK derivative securities

Traded Jul 13, 2026 · Filed Jul 14, 2026

CytokineticsCYTK

7,490
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jul 13, 2026
Reporting period: Not applicable
Filed with the SEC: Jul 14, 2026

CEOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001061983-26-000077

Filed / recorded

Jul 14, 2026, 7:34 PM UTC

Added to OQRO

Oct 6, 2026, 7:14 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

CYTOKINETICS INC

Issuer CIK

1061983

Ticker

CYTK

Reporting person

Robert I Blum

Relationship

Director, Officer

Officer title

President & CEO

Security

Non-Qualified Stock Option (Right to Buy)

Table

Derivative (Table II)

Transaction date

Jul 13, 2026

Transaction code

M

Shares / units

7,490

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

186,745

Ownership form

Direct

Amendment

No

Around the same time

Robert I BlumPresident & CEO

Filed 8w ago

7,500Shares · @ $10.60

Traded Aug 10 · filed the same day

Derivative exercise or conversion — not an open-market buy.

More Official record

Robert I Blum (President & CEO) sold ~$576K of Cytokinetics

Automatic saleFiled 8w ago

Robert I BlumPresident & CEO

Filed 8w ago

7,500Derivative units

Traded Aug 10 · filed the same day

Derivative exercise or conversion — not an open-market buy.

More Official record